Overview

Upadacitinib is positioned for the specific population of adults whose moderate to severe rheumatoid arthritis has not responded to conventional or biologic therapy, making patient selection the defining element of its use. REMATIB provides upadacitinib 15 mg prolonged-release tablets in 10-tablet boxes for once-daily dosing. This article details how prescribers identify the inadequate-responder cohort and what buyers should stock for this targeted group. Selecting the right patients is what turns a potent JAK inhibitor into measurable benefit.

How It Works

Upadacitinib is a selective JAK1 inhibitor delivered as a once-daily prolonged-release tablet, interrupting cytokine signalling pathways that sustain joint inflammation and structural damage. By preferentially blocking JAK1, it modulates interleukin-6, interferon, and related mediators more narrowly than pan-JAK drugs. For patients who have failed methotrexate or anti-TNF biologics, this targeted oral route offers an alternative mechanism when prior classes have plateaued. The prolonged-release formulation supports steady exposure from a single daily dose.

Indications

Upadacitinib is indicated for moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to methotrexate or tumour necrosis factor inhibitors, and for several other immune-mediated conditions per labelling. The 10-tablet pack covers the early phase of once-daily therapy. Eligibility rests on documented inadequate response to prior DMARDs, assessed before initiation.

Dosage & Administration

One 15 mg prolonged-release tablet is taken orally once daily, with or without food; the tablet is swallowed whole and not crushed or split. A 10-tablet box covers the initial ten days of therapy. Dose and continuation follow response and tolerability under monitoring for infections and lipids. Therapy is continuous and reviewed against treatment targets.

Storage & Sourcing

Store below 30°C in the original blister, away from moisture and light. Upadacitinib is prescription-only; B2B orders require licensed sourcing and market authorisation. Because the 10-tablet pack is small, buyers should forecast recurring monthly demand for the targeted responder cohort. Confirm batch expiry and certificate of analysis on receipt, and align supply with monitored outpatient use.

FAQ

Q: Which RA patients are candidates for upadacitinib? A: Adults with moderate to severe disease who have had inadequate response or intolerance to methotrexate or anti-TNF biologics are the primary targeted population.

Q: Why is the tablet formulated as prolonged-release? A: The prolonged-release design gives steady JAK1 inhibition from a single daily dose, supporting adherence in long-term outpatient therapy.

Q: How should buyers plan inventory for this product? A: The 10-tablet pack covers only ten days, so forecast recurring monthly orders aligned to the confirmed responder cohort rather than one-off stock.